Halt of Polyphor trial shrinks company valuation
Roche had a nose for success when the pharma giant ended the CHF500m deal with Polyphor in November 2015. Now, the antibiotics maker stopped a Phase III trial of its lead murepavadin (Pol7080).
MS linked to epigenetic changes in immune cells
Epigenetic changes in immune cells may provide the trigger of multiple sclerosis. Researchers have now identified MS-specific epigenetic biomarkers that change upon drug treatment.
Swiss Biotech Day 2019
The Swiss Biotech Day has long become the standard annual get-together of the Swiss biopharmaceutical industry. And Basel, as one of the most vivid cities in terms of biotechnological and pharmaceutical research, development and production, proved to be the ideal location.
Confo Therapeutics raise 30m in Series A financing
The round was led by BioGeneration Ventures and Wellington Partners, with Fund+, Perceptive Advisors and existing investors Capricorn Venture Partners, MINTS, PMV, QBIC and V-Bio Ventures contributing.
Researchers report how body fat affects imune cells
US scientists have found that the complex interactions between fat tissue and the immune system are mediated by interleukin 33 (IL-33).
European Lead Factory gets 36.5m support from IMI
The European Lead Factory (ELF) – a drug discovery hub for validation new targets from academia and biotech SMEs has again received project funding from the Innovative Medicine’s Initiative.
AstraZeneca set to licence 5 programmes from Transgène SA
Transgène SA and AstraZeneca plc have entered into a collaboration and exclusive license option agreement on Transgènes armed oncolytic immunotherapies.
Alentis Therapeutics debuts with CHF12.5m
Liver specialist Alentis Therapeutics AG has raised CHF12.5m in a Series A round co-led by BioMedPartners and BB Pureos Bioventures.
EMA recommends nine drugs for market approval
In its first meeting in Amsterdam, the CHMP of the European Medicines Agency recommended six new drugs, two orphan meds, and one biosimilar for EU market authorisation.
A novel strategy against rheumatoid arthritis
Researchers at AstraZeneca, Viela Bio, Gilead Sciences, Antidote Therapeutics Inc., and at SoseiHeptares report on a new small molecule compound to treat RA.